



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Corrigendum

## Corrigendum to “Review of trials currently testing treatment and prevention of COVID-19” [Clin Microbiol Infect 26.8 (2020) 988–998]

Paraskevi C. Fragkou<sup>1,2,\*</sup>, Drifa Belhadi<sup>3,4,†</sup>, Nathan Peiffer-Smadja<sup>3,5,‡</sup>, Charalampos D. Moschopoulos<sup>1,‡</sup>, François-Xavier Lescure<sup>3,5</sup>, Hannah Janocha<sup>6</sup>, Emmanouil Karofylakis<sup>1</sup>, Yazdan Yazdanpanah<sup>3,5</sup>, France Mentré<sup>3,4</sup>, Chrysanthi Skevaki<sup>2,6</sup>, Cédric Laouénan<sup>3,4,§</sup>, Sotirios Tsiodras<sup>1,2,§</sup>, on behalf of the ESCMID Study Group for Respiratory Viruses

<sup>1</sup> 4th Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece

<sup>2</sup> European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Respiratory Viruses (ESGREV), Switzerland

<sup>3</sup> Université de Paris, IAME, INSERM, F-75018, Paris, France

<sup>4</sup> Département d'Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat – Claude-Bernard, AP-HP, 75018, Paris, France

<sup>5</sup> Infectious Diseases Department, Bichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France

<sup>6</sup> Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Centre (UGMLC), Philipps University Marburg, German Centre for Lung Research (DZL), Marburg, Germany

The authors regret that at the “Transparency declaration” (p. 997) of the published paper, the conflicts of interest were unintentionally incomplete.

The following is the correct “Transparency declaration”: For Y.Y.:

Co-Chair of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) and the coordinator of REsearch and ACTION targeting emerging infectious diseases (REACTing); Presentations at workshops and consultancy honoraria from Abbvie, Gilead, Merck, J&J, and ViiV Healthcare but not since 2017. For C.S.: Consultancy and research funding, Hycor Biomedical and Thermo Fisher Scientific; Consultancy, Bencard Allergie; Research Funding, Mead Johnson Nutrition. Supported by Universities Giessen and Marburg Lung Centre (UGMLC), the German Center for Lung Research, University Hospital Giessen and Marburg research funding according to article 2, section 3 cooperation agreement, and the Deutsche Forschungsgemeinschaft-funded-SFB 1021 (C04), -KFO 309 (P10), and SK 317/1-1 (Project number 428518790) as well as by the Foundation for Pathobiochemistry and Molecular Diagnostics. For FXL: Payment for development of educational presentations, Gilead Sciences, Inc. and MSD (Merck Sharp & Dohme); Travel/accommodations/meeting expenses, Astellas Pharma Inc., Eumedita Pharmaceuticals, MSD (Merck Sharp & Dohme). For PCF: Research funding, Doctorate scholarship by the State Scholarships Foundation (IKY), Partnership Agreement (PA) 2014–2020, co-financed by Greece and the European Union (European Social Fund - ESF) through the Operational Programme “Human Resources Development, Education and Lifelong Learning 2014–2020”. All grants are outside the submitted work. No external funding was received for this study.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.cmi.2020.05.019>.

\* Corresponding author: P.C. Fragkou, ESGREV member, 4th Department of Internal Medicine, Attikon University Hospital, 1 Rimini Str, Chaidari, Athens, 12462, Greece.

E-mail addresses: [evita.fragkou@gmail.com](mailto:evita.fragkou@gmail.com) (P.C. Fragkou), [drifa.belhadi@aphp.fr](mailto:drifa.belhadi@aphp.fr) (D. Belhadi), [nathan.peiffer-smadja@inserm.fr](mailto:nathan.peiffer-smadja@inserm.fr) (N. Peiffer-Smadja), [bmosxop@yahoo.gr](mailto:bmosxop@yahoo.gr) (C.D. Moschopoulos), [xavier.lesecure@aphp.fr](mailto:xavier.lesecure@aphp.fr) (F.-X. Lescure), [hannah.janocha@med.uni-giessen.de](mailto:hannah.janocha@med.uni-giessen.de) (H. Janocha), [manoskarofylakis@gmail.com](mailto:manoskarofylakis@gmail.com) (E. Karofylakis), [yazdan.yazdanpanah@aphp.fr](mailto:yazdan.yazdanpanah@aphp.fr) (Y. Yazdanpanah), [france.mentre@inserm.fr](mailto:france.mentre@inserm.fr) (F. Mentré), [Chrysanthi.Skevaki@uk-gm.de](mailto:Chrysanthi.Skevaki@uk-gm.de) (C. Skevaki), [cedric.laouenan@inserm.fr](mailto:cedric.laouenan@inserm.fr) (C. Laouénan), [sotirios.tsiodras@gmail.com](mailto:sotirios.tsiodras@gmail.com) (S. Tsiodras).

† Equal contribution as first authors.

‡ Equal contribution as second authors.

§ Equal contribution as senior authors.

<https://doi.org/10.1016/j.cmi.2021.01.024>

1198-743X/© 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.